Cephalon, Barr End Clash Over Provigil

Law360, New York (February 2, 2006, 12:00 AM EST) -- Trying to stave off generic competition for as long as possible, Cephalon has reached another settlement over the narcolepsy drug Provigil, this time with generic drug maker Barr Pharmaceuticals Inc.

On Wednesday, Cephalon announced that it had entered into a nonexclusive licensing agreement with Barr for Provigil, only weeks after the company brokered a similar agreement with Mylan Pharmaceuticals Inc. for the sleep disorder drug.

As part of the deal, Cephalon also agreed to sweeten a pre-existing arrangement with Barr over the pain reliever drug Actiq....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.